Stocks News

LAST PRICE
75.4500
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
56.5000/ 1
Ask / Lots
81.7800/ 1
Open / Previous Close
71.4900 / 75.4500
Day Range
Low 71.1525
High 75.8300
52 Week Range
Low 44.2000
High 82.0400
Volume
1,140,727
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 9, 2024
- DJ Vaxcyte Price Target Maintained With a $95.00/Share by Needham, from 6:53AM ET on Thursday May 09, 2024 by Dow Jones
  6:53AM ET on Thursday May 09, 2024 by Dow Jones
  Companies Mentioned: PCVX
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/PCVX/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 09, 2024 06:53 ET (10:53 GMT)
May 8, 2024
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday May 08, 2024 by GlobeNewswire
  4:05PM ET on Wednesday May 08, 2024 by GlobeNewswire
  Companies Mentioned: PCVX
- *DJ Vaxcyte 1Q Loss/Shr 85c >PCVX, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
  4:05PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: PCVX
  
  Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte's lead candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company's next-generation 31-valent PCV, is the broadest-spectrum PCV candidate in the clinic today. Both VAX-24 and VAX-31 are designed to improve upon the standard-of-care PCVs for both children and adults by covering the serotypes that are responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
- Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones
  4:05PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: PCVX
  
  Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte's lead candidate, VAX-24, is a Phase 3-ready 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company's next-generation 31-valent PCV, is the broadest-spectrum PCV candidate in the clinic today. Both VAX-24 and VAX-31 are designed to improve upon the standard-of-care PCVs for both children and adults by covering the serotypes that are responsible for a significant portion of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Apr 25, 2024
- Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing, from 4:56PM ET on Thursday Apr 25, 2024 by MT Newswires
  4:56PM ET on Thursday Apr 25, 2024 by MT Newswires
  Companies Mentioned: PCVX
  04:56 PM EDT, 04/25/2024 (MT Newswires) -- Grant Pickering, Director, CEO, on April 23, 2024, sold 15,000 shares in Vaxcyte (PCVX) for $928,845. Following the Form 4 filing with the SEC, Pickering has control over a total of 772,571 shares of the co...

Yesterday
- ACQUISITION ALERT BFA LLP Notifies Cerevel Therapeutics Shareholders of an Investigation into the Merger with AbbVie, from 9 hours ago by Accesswire
  9 hours ago by Accesswire
  Companies Mentioned: CERE
- BFA LLP Reminds Cerevel Therapeutics Shareholders of the Investigation into Merger with AbbVie and Encourages Investors to Contact the Firm, from 17 hours ago by Newsfile
  17 hours ago by Newsfile
  Companies Mentioned: CERE
May 15, 2024
- MERGER NEWS NASDAQ CERE BFA Law Investigates Cerevel Therapeutics Merger with AbbVie Encourages Shareholders to Contact the Firm, from 4:09PM ET on Wednesday May 15, 2024 by Accesswire
  4:09PM ET on Wednesday May 15, 2024 by Accesswire
  Companies Mentioned: CERE
- MERGER ALERT CERE Is $45 per CERE Share Fair? Top Law Firm BFA LLP Investigating Cerevel Therapeutics Merger with AbbVie, from 8:33AM ET on Wednesday May 15, 2024 by Newsfile
  8:33AM ET on Wednesday May 15, 2024 by Newsfile
  Companies Mentioned: CERE
- Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024, from 7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire
  7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire
  Companies Mentioned: CYTK
May 14, 2024
- Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing, from 5:23PM ET on Tuesday May 14, 2024 by MT Newswires
  5:23PM ET on Tuesday May 14, 2024 by MT Newswires
  Companies Mentioned: CERE
- NASDAQ CERE INVESTIGATION ALERT Leading Law Firm BFA LLP Notifies CERE Shareholders of Investigation into the Cerevel Therapeutics Merger with AbbVie Contact Firm for More Information, from 4:04PM ET on Tuesday May 14, 2024 by Accesswire
  4:04PM ET on Tuesday May 14, 2024 by Accesswire
  Companies Mentioned: CERE
- CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough? Bleichmar Fonti & Auld LLP is Currently Investigating the Acquisition, from 8:33AM ET on Tuesday May 14, 2024 by GlobeNewswire
  8:33AM ET on Tuesday May 14, 2024 by GlobeNewswire
  Companies Mentioned: CERE
May 13, 2024
- CEREVEL THERAPEUTICS HOLDINGS, INC. (CERE) ACQUISITION ALERT: Is AbbVie Inc.'s Offer of $45 per CERE Share a Fair Deal? Bleichmar Fonti & Auld LLP is Currently Investigating the Acquisition, from 9:07PM ET on Monday May 13, 2024 by Newsfile
  9:07PM ET on Monday May 13, 2024 by Newsfile
  Companies Mentioned: CERE
- Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress, from 9:33AM ET on Monday May 13, 2024 by GlobeNewswire
  9:33AM ET on Monday May 13, 2024 by GlobeNewswire
  Companies Mentioned: CYTK

Vaxcyte Inc
NASDAQ:PCVXUnited States

Search Criteria

May 9, 2024

DJ Vaxcyte Price Target Maintained With a $95.00/Share by Needham, from 6:53AM ET on Thursday May 09, 2024 by Dow Jones

May 8, 2024

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday May 08, 2024 by GlobeNewswire

*DJ Vaxcyte 1Q Loss/Shr 85c >PCVX, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday May 08, 2024 by Dow Jones

Apr 25, 2024

Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing, from 4:56PM ET on Thursday Apr 25, 2024 by MT Newswires

Peers Headlines

Yesterday

ACQUISITION ALERT BFA LLP Notifies Cerevel Therapeutics Shareholders of an Investigation into the Merger with AbbVie, from 9 hours ago by Accesswire

BFA LLP Reminds Cerevel Therapeutics Shareholders of the Investigation into Merger with AbbVie and Encourages Investors to Contact the Firm, from 17 hours ago by Newsfile

May 15, 2024

MERGER NEWS NASDAQ CERE BFA Law Investigates Cerevel Therapeutics Merger with AbbVie Encourages Shareholders to Contact the Firm, from 4:09PM ET on Wednesday May 15, 2024 by Accesswire

MERGER ALERT CERE Is $45 per CERE Share Fair? Top Law Firm BFA LLP Investigating Cerevel Therapeutics Merger with AbbVie, from 8:33AM ET on Wednesday May 15, 2024 by Newsfile

Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024, from 7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire

May 14, 2024

Cerevel Therapeutics Holdings Insider Sold Shares Worth $2,105,125, According to a Recent SEC Filing, from 5:23PM ET on Tuesday May 14, 2024 by MT Newswires

NASDAQ CERE INVESTIGATION ALERT Leading Law Firm BFA LLP Notifies CERE Shareholders of Investigation into the Cerevel Therapeutics Merger with AbbVie Contact Firm for More Information, from 4:04PM ET on Tuesday May 14, 2024 by Accesswire

CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share Enough? Bleichmar Fonti & Auld LLP is Currently Investigating the Acquisition, from 8:33AM ET on Tuesday May 14, 2024 by GlobeNewswire

May 13, 2024

CEREVEL THERAPEUTICS HOLDINGS, INC. (CERE) ACQUISITION ALERT: Is AbbVie Inc.'s Offer of $45 per CERE Share a Fair Deal? Bleichmar Fonti & Auld LLP is Currently Investigating the Acquisition, from 9:07PM ET on Monday May 13, 2024 by Newsfile

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress, from 9:33AM ET on Monday May 13, 2024 by GlobeNewswire